Moreover, we observed a secondary T790M EGFR mutation in lung adenocarcinoma (LUAD) and resistance to EGFR-targeted therapies (Gefitinib and Afatinib) (Godin-Heymann et al., 2008) (Figure 4D), as well as resistance of NRAS mutated melanoma patients to a BRAF inhibitor (Figure 4B; Table S4C) (Su et al., 2012). This evidence concerns the gene NRAS and melanoma.